Histogenics Corp. believes that the US FDA will accept data from a Phase III study of its knee cartilage cell therapy NeoCart for review, even though the study failed the primary endpoint, because the firm believes the data meet a lower bar for approval now accepted by the agency.
The company will be requesting a "Type A" informational meeting with the FDA after reporting results from a Phase III...